Researchers at the University of Sydney have published what they describe as the largest-ever review of medicinal cannabis for mental health conditions, and the results challenge a popular assumption: there is no reliable evidence that cannabis-based treatments help people with PTSD, anxiety, or depression. The review, led by Jack Wilson of the Matilda Centre, was published in The Lancet Psychiatry and arrives at a time when patients in the United States, Australia, and Canada are increasingly turning to medical cannabis for psychiatric symptoms. The findings raise hard questions about whether millions of people are choosing an unproven option while delaying treatments with stronger evidence behind them.
What the Largest Cannabis Mental Health Review Found
The University of Sydney team examined 83 studies involving more than 3,000 patients, making it the most extensive assessment of cannabis safety and efficacy for these three conditions to date, according to university researchers. While some individual studies reported short-term symptom relief, the data overall lacked the rigor needed to support clinical recommendations. No consistent long-term benefits emerged across the body of evidence.
Jack Wilson, the study’s lead author, framed the results as a call for better science rather than a blanket dismissal. His comments, reported by ScienceDaily coverage, pointed to specific harms that concern researchers: the risk of psychosis, the potential for cannabis use disorder, and the danger that patients delay evidence-based care such as cognitive behavioral therapy or antidepressant medication. The review did not claim cannabis is universally harmful, but it concluded that the available research cannot justify prescribing it for anxiety, depression, or PTSD.
Side Effects: Mostly Mild, but Safety Gaps Persist
One finding that may reassure some patients is that most side effects observed across the reviewed studies were mild to moderate, according to an analysis in The Conversation by members of the research team. Drowsiness, dry mouth, and dizziness were among the most commonly reported complaints. That profile is not dramatically different from what patients experience with many conventional psychiatric medications.
Yet the same analysis noted that serious questions about safety remain unanswered. The studies reviewed were generally small, short in duration, and inconsistent in how they tracked adverse events. Without large-scale, long-term randomized controlled trials, it is difficult to know whether rarer but more severe outcomes, such as psychotic episodes or dependency, occur at meaningful rates in psychiatric populations. The absence of clear harm is not the same as proof of safety, and the review’s authors were careful to draw that distinction.
VA Guidelines Already Warned Against Cannabis for PTSD
The new review aligns with guidance that the U.S. Department of Veterans Affairs and Department of Defense issued in 2023. The joint guideline for PTSD management explicitly recommends against treating the condition with cannabis or cannabis-derived products. That recommendation rests on two pillars: insufficient evidence that cannabis works for PTSD and documented risks that outweigh any potential benefit.
The VA’s clinical resources on marijuana use among veterans spell out the rationale in detail. Veterans represent one of the populations most affected by PTSD, and many have turned to cannabis in states where it is legal, sometimes as a substitute for therapies with stronger evidence. The VA does not prohibit veterans from using cannabis where state law allows it, but clinicians are directed not to recommend it as a treatment. The gap between patient demand and clinical endorsement has been a source of tension for years, and the Sydney review adds fresh weight to the skeptical side of that debate.
A Conflicting Signal From Canadian Data
Not all research points in the same direction. A Canadian observational study published in Psychiatry Research found that patients seeking medical cannabis for anxiety reported improved outcomes over time, according to the study abstract. On its face, this seems to contradict the Sydney team’s conclusion.
The tension between these findings is less dramatic than it appears. Observational studies track what happens to patients who choose a treatment on their own, without a control group receiving a placebo. Patients who seek out cannabis may also be making other lifestyle changes, engaging with healthcare providers more frequently, or experiencing a natural improvement in symptoms over time. The Sydney review, by contrast, weighed the totality of evidence across study designs and found that when stricter standards were applied, the positive signals faded. This is a familiar pattern in medical research: early observational hints of benefit often do not survive the scrutiny of controlled trials.
Both sets of findings deserve attention, but they answer different questions. The Canadian data suggest that some patients feel better after starting cannabis. The Sydney review asks whether cannabis itself is responsible for that improvement, and it answers: the evidence is not there yet.
Why Patients Keep Choosing Cannabis Anyway
The disconnect between clinical evidence and patient behavior is not hard to explain. Standard treatments for PTSD, anxiety, and depression, including selective serotonin reuptake inhibitors and trauma-focused psychotherapy, do not work for everyone. Side effects from conventional medications can be significant. Wait times for specialized therapy, particularly in rural areas or through the VA health system, can stretch for weeks or months. Against that backdrop, cannabis can look like a more accessible, more natural, and more controllable option, especially in jurisdictions where dispensaries are common and marketing is aggressive.
Stigma also plays a role. Some people are reluctant to pursue formal mental health care because they fear being labeled or worry about consequences for employment, security clearances, or insurance. Buying cannabis from a legal retailer or obtaining a medical authorization can feel less exposing than enrolling in a structured therapy program. For veterans, navigating benefits and services can be confusing, even with centralized resources such as the VA’s online help center, so a straightforward commercial product may seem simpler than working through official channels.
Another factor is perception of risk. Many people view cannabis as benign compared with alcohol, opioids, or benzodiazepines. Stories of friends or social media influencers who report dramatic relief after using cannabis for panic attacks or nightmares can be more persuasive than abstract discussions of evidence quality. In the absence of clear, consistent messaging from clinicians, those anecdotes often fill the vacuum.
What Evidence-Based Alternatives Look Like
None of this means patients with PTSD, anxiety, or depression are wrong to seek relief, or that they should be forced into one-size-fits-all treatments. But the Sydney review underscores that decisions about cannabis should be made with eyes open. For PTSD in particular, the VA and DoD guidelines emphasize trauma-focused psychotherapies, such as prolonged exposure and cognitive processing therapy, as first-line options, with certain medications as second-line support.
Access to these therapies varies. Some veterans can receive care through large medical centers, while others rely on regional facilities listed in the VA’s network of clinics. Community-based counseling is also available at Vet Center locations, which focus on readjustment and combat-related stress. Outside the VA, many countries maintain similar stepped-care models that prioritize psychological therapies and reserve medications for specific indications.
For anxiety and depression, the evidence base is broader but follows the same pattern: structured psychotherapies and certain antidepressants have been tested in large trials and show clear, if imperfect, benefits. By contrast, cannabis products vary widely in composition, dose, and route of administration, making it difficult to standardize treatment or compare results. The Sydney team’s review found that this heterogeneity further undermined the strength of the evidence.
How Patients and Clinicians Can Navigate the Uncertainty
For individuals already using cannabis for mental health symptoms, the review does not mandate an abrupt stop. Instead, it suggests a conversation with a clinician about what is known, what remains uncertain, and what other options might be worth trying. Veterans and their families can raise these questions with providers at VA hospitals and clinics, or by contacting regional offices listed on the VA’s regional contact page if they are unsure where to start.
Clinicians, for their part, face the challenge of acknowledging patients’ lived experiences without overstating what the science supports. That may mean validating that someone feels calmer after using cannabis while also explaining that the effect could be temporary, placebo-driven, or offset by longer-term risks. It also means being transparent about the limits of current knowledge and the need for more rigorous trials, rather than defaulting to blanket endorsements or categorical rejections.
The University of Sydney review does not close the book on medicinal cannabis for mental health, but it does reset the baseline. Until better evidence emerges, cannabis should be viewed less as a proven therapy and more as an experimental option whose benefits and risks are still being mapped. For patients weighing their choices, that distinction matters: hope is important, but so is clarity about what the science can and cannot yet promise.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
